Completed × Hodgkin Disease × Other hematologic neoplasm × Clear all Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
Completed
1,340 enrolled
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled 15 charts
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
Phase 1 Completed
85 enrolled
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
Phase NA Completed
30 enrolled
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Phase 2 Completed
47 enrolled 8 charts
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
Phase 1/2 Completed
55 enrolled 17 charts
BMT
Phase NA Completed
10 enrolled
RELATIVITY-069
Phase 1/2 Completed
5 enrolled
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Phase 1 Completed
13 enrolled
BMT CTN 1702
Phase NA Completed
1,753 enrolled
KEYNOTE145
Phase 1/2 Completed
161 enrolled 29 charts
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1 Completed
14 enrolled
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
Phase 1 Completed
50 enrolled
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
AYAConnect
Phase NA Completed
63 enrolled
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Phase 1/2 Completed
34 enrolled 18 charts
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
Completed
11 enrolled
Haplo Peripheral Blood Sct In GVHD Prevention
Phase 1 Completed
25 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
Phase 2 Completed
28 enrolled 10 charts
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
Completed
100 enrolled
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
35 enrolled 14 charts
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Phase 2 Completed
46 enrolled
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Phase 1 Completed
55 enrolled 11 charts
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 2 Completed
61 enrolled 10 charts
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Phase NA Completed
8 enrolled
MinimALL
Phase NA Completed
27 enrolled
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Phase 1 Completed
20 enrolled
MargheRITA
Phase NA Completed
124 enrolled
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Phase 2 Completed
112 enrolled
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Phase 1 Completed
106 enrolled
UK-Haplo
Phase 2 Completed
77 enrolled
SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed
26 enrolled
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Phase 1 Completed
36 enrolled
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1 Completed
16 enrolled
EMATO0113
Completed
141 enrolled
PROSECO
Completed
592 enrolled
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Phase 2 Completed
22 enrolled 15 charts
Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Phase 2 Completed
37 enrolled 6 charts
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Phase 1 Completed
29 enrolled
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
Phase 1 Completed
16 enrolled
FUSION NHL 001
Phase 1/2 Completed
106 enrolled 48 charts
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Phase 2 Completed
50 enrolled 23 charts
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Completed
10 enrolled 3 charts
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Phase 2 Completed
23 enrolled 10 charts